The FDA has expanded clearance for an accelerated treatment protocol for the noninvasive Deep Transcranial Magnetic Stimulation (Deep TMS, BrainsWay) system for depressive episodes and anxiety ...
Despite missing the primary endpoint, the novel K V 7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback